5.1 Antineoplastic Principles, Dosing & Dose Adjustments

3.1 Antineoplastic Principles, Dosing & Dosing Adjustments

Clinical Pearl: Underdosing obese oncology patients based on arbitrary "capped" Body Surface Area (BSA) limits is a major driver of sub-therapeutic treatment outcomes and compromised survival. ASCO guidelines explicitly recommend calculating chemotherapy doses using actual body weight across all body mass index (BMI) categories, managing toxicities through standard dose-reduction protocols rather than baseline empirical capping.

Cell Cycle Kinetics & Chemotherapy Principles

Antineoplastic pharmacodynamics are governed by cellular growth kinetics and cell cycle specificity. Malignant tumors initially follow Gompertzian growth kinetics, demonstrating rapid exponential growth at low tumor burdens, followed by a plateau in growth rate as the tumor outgrows its vascular supply and nutrient availability.

According to the Log-Kill Hypothesis, a given dose of cytotoxic chemotherapy kills a constant fraction (percentage) of tumor cells rather than a constant number of cells. Consequently, multiple sequential cycles of therapy are necessary to reduce the tumor burden to a level manageable by host immune surveillance.

Tumor Cell Burden
  │
  ├─► [Cycle 1: 3-Log Kill] ──► 99.9% Killed (10^9 to 10^6 cells)
  │
  ├─► [Cycle 2: 3-Log Kill] ──► 99.9% Killed (10^6 to 10^3 cells)
  │
  └─► [Cycle 3: 3-Log Kill] ──► 99.9% Killed (10^3 to 10^0 cells -> Remission)

Cell Cycle-Specific (CCS) vs. Cell Cycle-Nonspecific (CCNS) Agents

Antineoplastic agents are categorized by their phase specificity within the cell cycle:

• Cell Cycle-Specific (CCS) Agents: Exert cytotoxicity exclusively during specific phases of the cell cycle (e.g., S-phase for antimetabolites like 5-FU and methotrexate; M-phase for taxanes and vinca alkaloids; G2/M-phase for bleomycin). CCS agents are schedule-dependent; prolonged exposure or continuous infusions maximize tumor cell kill as cells asynchronously enter the sensitive phase.
• Cell Cycle-Nonspecific (CCNS) Agents: Exert cytotoxic effects throughout all phases of the cell cycle, including the resting G0 phase (e.g., alkylating agents such as cyclophosphamide and mechlorethamine; platinum analogs like cisplatin; antitumor antibiotics like doxorubicin). CCNS agents are dose-dependent; cytotoxicity directly correlates with peak drug concentration.

---

Dosing Methodologies & Formula Calculations

Body Surface Area (BSA) Dosing

Most cytotoxic antineoplastic agents are dosed based on Body Surface Area (m²) to standardize systemic drug exposure while accounting for metabolic rate. The Mosteller formula is the most widely utilized clinical calculation:

$\text{BSA (m}^2\text{)} = \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}}$

Clinical Practice Rule: For obese patients (BMI ≥ 30 kg/m²), APRNs must use actual total body weight to calculate BSA. Historical practices of capping BSA at 2.0 m² or using ideal body weight result in underdosing and reduced disease-free survival.

Carboplatin AUC Dosing (The Calvert Formula)

Carboplatin dosing is unique because its clearance is almost exclusively renal and directly proportional to Glomerular Filtration Rate (GFR). To achieve a target Area Under the Concentration-Time Curve (AUC) while avoiding severe myelosuppression, carboplatin is dosed using the Calvert Formula:

$\text{Total Carboplatin Dose (mg)} = \text{Target AUC} \times (\text{GFR} + 25)$

1. Estimating GFR: Clinical practice utilizes the Cockcroft-Gault equation to estimate Creatinine Clearance (CrCl), which serves as the surrogate for GFR:

$\text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times \text{Serum Creatinine (mg/dL)}} \times (0.85 \text{ for females})$

1. FDA GFR Cap Rule: To prevent severe carboplatin toxicity in patients with hyperfiltering or normal renal function, the maximum GFR used in the Calvert formula is capped at 125 mL/min. Thus, the maximum allowable carboplatin dose for a target AUC is:

$\text{Max Dose (mg)} = \text{Target AUC} \times (125 + 25) = \text{Target AUC} \times 150$

---

Organ-Based Dose Adjustments

Systemic antineoplastics undergo hepatic metabolism and/or renal excretion. Failure to adjust doses in patients with organ dysfunction leads to lethal toxicities.

Hepatic Dysfunction Dose Adjustments

Hepatic clearance is primarily evaluated via Total Bilirubin and transaminases (AST/ALT). Biliary excretion is the major elimination pathway for anthracyclines, vinca alkaloids, and taxanes.

Renal Dysfunction Dose Adjustments

Renal clearance is critical for platinum compounds, antimetabolites, and alkylating agents.

• Cisplatin: Highly nephrotoxic; contraindicated when CrCl < 50-60 mL/min. Substitute with carboplatin or reduce dose significantly.
• High-Dose Methotrexate: Requires CrCl > 60 mL/min. Delayed renal excretion causes profound marrow aplasia and mucositis. Maintain urine output > 100 mL/hr and urine pH ≥ 7.0 using sodium bicarbonate IV.
• Ifosfamide & Cyclophosphamide: Metabolite acrolein cleared renally. Reduce dose by 25–50% for CrCl < 30 mL/min.

---

Pharmacogenomics & Safety Biomarkers

Pre-treatment pharmacogenomic screening identifies hereditary enzymatic deficiencies that impair antineoplastic drug clearance, preventing fatal toxicities.

Dihydropyrimidine Dehydrogenase (DPYD) Deficiency

• Gene / Enzyme: DPYD gene encodes DPD, the rate-limiting enzyme responsible for metabolizing >80% of fluoropyrimidines (5-Fluorouracil [5-FU] and oral prodrug Capecitabine).
• Clinical Risk: Heterozygous or homozygous loss-of-function variants (DPYD *2A, *13, c.2846A>T) result in severe, potentially fatal toxicities: Grade 4 mucositis, intractable diarrhea, severe pancytopenia, and neurotoxicity within days of exposure.
• Action: Test DPYD variants prior to initiating 5-FU/capecitabine. Heterozygotes require a 25–50% initial dose reduction; homozygotes require complete avoidance.

UGT1A1 Polymorphisms & Irinotecan

• Gene / Enzyme: UDP-glucuronosyltransferase 1A1 (UGT1A1) metabolizes SN-38 (active toxic metabolite of irinotecan) into inactive SN-38G.
• Clinical Risk: The UGT1A1*28 allele reduces gene expression. Homozygous individuals (UGT1A128/*28, Gilbert syndrome phenotype) experience severely impaired SN-38 clearance.
• Action: Patients homozygous for UGT1A128 receiving medium-to-high dose irinotecan (≥ 180 mg/m²) require an initial dose reduction of at least 1 dose level (e.g., 20–25%) to prevent severe neutropenia and life-threatening diarrhea.

Thiopurine S-Methyltransferase (TPMT) & NUDT15

• Gene / Enzyme: TPMT and NUDT15 metabolize thiopurines (6-Mercaptopurine, 6-Thioguanine).
• Clinical Risk: Deficiency leads to accumulation of toxic thioguanine nucleotides, causing fatal bone marrow failure.
• Action: Mandatory screening before thiopurine therapy; homozygous deficient patients require a 90% dose reduction (10% of standard dose).